OAG Acquires Infare and Receives New Investment from Vitruvian Partners
OAG, the world’s leading data platform for the global travel industry, has acquired Infare, the leading provider of competitor air travel data, from Ventiga Capital in a deal valuing the combined entity at over US$500m. Together, OAG and Infare have an exciting journey ahead to leverage a truly market-leading end-to-end data platform to serve mission-critical air travel intelligence needs across the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230728627752/en/
With renowned industry heritage, both businesses share a deep passion for quality, accuracy, and customer-centricity. Together, there is a significant opportunity for OAG and Infare to better serve airline partners and the wider travel ecosystem with high-quality data and innovative solutions.
Infare is the partner of choice for airlines demanding the highest quality competitor air travel data source to support their growth. Combining OAG’s existing data solutions with airfare data creates a compelling proposition for customers who can get a broader picture of supply and demand. This enables customers to forecast resource, evaluate travel demand and competition, and build more complex and innovative models to drive revenue and profitable growth.
Through the acquisition, OAG now grows to over 300 employees globally across 10 offices.
Phil Callow, CEO of OAG, commented:
“The increasing dynamism in global travel and technology is fuelling a need for more sophisticated, granular data to understand, manage and unlock growth in air travel. The acquisition of Infare strengthens our ability to deliver consistent and accurate information across the wider supply and demand value chain. Together, we are enabling new and existing customers to thrive and innovate ahead of their counterparts. I am excited to welcome Infare colleagues to the OAG family.”
Nils Gelbjerg-Hansen, CEO of Infare, commented:
“Access to comprehensive and accurate data is paramount for making informed business decisions. Airlines rely on data to gain valuable insights into customer behaviour, market trends, and operational efficiency. Our technology platform, data sets, and intelligence software complement OAG’s and will greatly benefit our customers worldwide. We see this as a unique opportunity to expand our services and introduce new innovative products for our customers, we are excited about the journey ahead together.”
Both management teams will continue in the Group and will retain a shareholding, with fresh backing provided by Vitruvian Partners.
Ben Johnson, a Partner at Vitruvian, commented:
“OAG and Infare are both clear leaders in their respective global markets. The combination creates additional growth opportunities for both teams. Vitruvian is delighted to support this ambitious technology company and renew our relationship with them for the years to come.”
Niclas Gabrán, Managing Partner at Ventiga Capital Partners, commented:
“It has been a pleasure working together with Nils and his team to build Infare into a leading travel data provider through organic growth and acquisitions. Infare’s next chapter as a part of the OAG family will undoubtedly create further growth opportunities both within and outside the air travel sector.”
About OAG
OAG is the leading data platform for the global travel industry, powering the growth and innovation of the air travel ecosystem since 1929. It has the world’s largest network of flight information, covering the whole journey from planning to customer experience. Customers include airlines, airports, travel technology players, aviation service providers, government agencies, financial institutions, and consultancies. Headquartered in the UK, OAG has operations in the USA, Singapore, Japan, China, and Lithuania. For more information, visit: www.oag.com and follow us on Twitter @OAG Aviation.
About Infare
Infare is the leading competitor air travel data provider, empowering airlines to make effective pricing decisions. Infare’s mission is to fuel airline systems with high-quality competitor air travel data delivered daily, multiple times a day or live. Founded in 2000 and headquartered in Copenhagen, Denmark, the company has a global reach and presence worldwide. For more information, visit www.infare.com and follow us on LinkedIn.
About Vitruvian Partners
Vitruvian is an independent growth capital firm headquartered in London with a global presence. Vitruvian focuses on dynamic situations characterized by rapid growth and change across industries spanning technology, financial services, healthcare, and business and consumer services. Vitruvian is among the largest pools of capital in Europe supporting innovative and higher growth companies. Vitruvian Funds have backed over 90 companies and have assets under management of €15+ billion. Notable investments to date include global market leaders and innovators in their field such as Skyscanner, Sykes Holiday Cottages, CFC Underwriting, CallCredit, Travel Counsellors, Trustpilot, Farfetch, Just Eat, Wise, and Global-e.
About Ventiga Capital Partners
Ventiga is an entrepreneurial and growth-focused investor partnering with exceptional entrepreneurs and management teams to achieve sustainable, profitable growth and transformational value through active, engaged, and responsible ownership. Ventiga invests in profitable growth companies with superior business expansion potential, primarily in the B2B services space.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230728627752/en/
Contact information
Media Enquiries
pressoffice@oag.com
UK/EMEA /ASPAC
Dom Conolly/ Harvard PR
North America
Chrissy Azevedo
Corporate Ink for OAG
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CorriXR Therapeutics, InhaTarget Therapeutics, and Merxin Ltd Announce Strategic Collaboration for the Development of Inhaled Lung Cancer Treatment2.12.2025 15:30:00 EET | Press release
CorriXR Therapeutics, an oncology-focused biotherapeutics company pioneering a ground-breaking gene editing platform technology, InhaTarget Therapeutics, a company dedicated to the early development and clinical validation of innovative treatments of pulmonary diseases by inhalation, and Merxin Ltd, a designer and supplier of inhaler devices, have entered a strategic collaboration to develop a pioneering inhaled genetic therapy targeting lung cancer. The partnership draws upon CorriXR’s proprietary CRISPR-based gene editing platform targeting NRF2, InhaTarget’s proprietary formulation platform and strong experience in pulmonary drug development, and Merxin Ltd’s advanced inhalation device technology. Through their combined expertise, they aim to create a patient-friendly inhaled therapy that delivers targeted treatment directly to lung tumors, maximizing efficacy, minimizing systemic side effects, and offering new hope for patients facing one of the world’s deadliest cancers. Innovativ
AdvanCell Initiates Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer2.12.2025 15:00:00 EET | Press release
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the initiation of the TheraPb Phase 2 expansion trial (NCT05720130) evaluating its lead investigational candidate, ADVC001, in metastatic prostate cancer. The news follows the encouraging Phase 1b dose escalation results presented at the European Society for Medical Oncology (ESMO) 2025 congress that showed a favorable safety profile and compelling anti-tumor activity for ADVC001 in patients with mCRPC (see press release). ADVC001 is a first-in-class 212Pb-PSMA RLT in clinical development, with early data indicating a differentiated and competitive profile both within and beyond its class. Development is advancing rapidly; the Phase 1b therapeutic cohorts were enrolled within ten months, and the commencement of Phase 2 expansion sustains this strong program momentum. The TheraPb Phase 2 expansion will evaluate ADVC001 at two therapeutic dose levels – 160 MB
Luma AI Opens for International Business With Former WPP Executive Jason Day Leading New London Office2.12.2025 15:00:00 EET | Press release
Luma AI, the frontier artificial intelligence company building multimodal AGI intelligence and known for its flagship product Dream Machine, today announced a major step in its global expansion with the opening of its first international office in London, UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202217704/en/ LUMA AI OPENS FOR INTERNATIONAL BUSINESS WITH FORMER WPP EXECUTIVE JASON DAY LEADING NEW LONDON OFFICE As creative economies decentralize and new production hubs emerge across EMEA, Luma AI is positioning its capabilities where creative work is increasingly being produced - not just consumed. To build intelligence that truly serves global creators, Luma AI will work alongside them in their markets, cultures, and workflows. London is the first step in that strategy, as it has the unique position as a global center of advertising, brands, and entertainment. “With this Series C raise and the upcoming build-out
Aurigene Oncology Limited Announces Encouraging Initial Data From 1 st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies2.12.2025 15:00:00 EET | Press release
Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology,today announced initial clinical results from 1st two cohorts of its ongoing Phase 1 clinical trial evaluating AUR112 in patients with relapsed or refractory lymphoid malignancies. Early findings show that AUR112 is safe, well tolerated, demonstrating meaningful clinical activity, with objective responses observed across multiple lymphoma subtypes, including Mantle Cell Lymphoma (MCL) and Marginal Zone Lymphoma (MZL). “We are very encouraged by the early results of the first two cohorts from our Phase 1 study of AUR112,” said Dr. Murali Ramachandra, CEO. “AUR112 has shown a promising initial clinical profile, achieving an overall response rate of 63.6% in the efficacy-evaluable population and 58.3% in the intent-to-treat group. These strong early data, combined with its distinct preclinical and safety characteristics, reinforce our belief that AUR112 has the potential to become
Eventbrite Enters into Definitive Agreement to Be Acquired by Bending Spoons for Roughly $500 Million to Accelerate Eventbrite’s Next Phase of Growth2.12.2025 14:30:00 EET | Press release
Eventbrite, Inc. (NYSE: EB), the leading global marketplace for shared experiences, announced today that it has entered into a definitive agreement to be acquired by Bending Spoons, in an all-cash transaction valued at approximately $500 million. The acquisition is subject to customary closing conditions and approvals, including regulatory approvals and approval by Eventbrite’s stockholders. “For two decades, Eventbrite has stood at the forefront of the experience economy, helping tens of millions to create, discover, and attend unforgettable events,” said Luca Ferrari, Bending Spoons CEO and Co-Founder. “Joining forces with Bending Spoons will accelerate innovation and strengthen Eventbrite’s tools and resources to bring even more people together through shared live experiences for many years to come. As longstanding fans, we’ve identified a few opportunities that we’re excited about exploring with the Eventbrite team after closing the transaction. These include building a dedicated m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom